GEN Exclusives

More »

GEN News Highlights

More »
Jun 7, 2007

Amgen to Acquire Alantos Pharmaceuticals for $300 Million

  • Amgen agreed to acquire Alantos, a private company developing drugs for the treatment of diabetes and inflammatory diseases. Alantos' lead drug candidate, ALS 2-0426, is a DPP-IV inhibitor in clinical development (Phase IIa) for the treatment of type 2 diabetes.

    Under terms of the agreement, Amgen will pay $300 million in cash to acquire Alantos. Following completion of the transaction, Alantos will become a wholly owned subsidiary of Amgen. The acquisition has been approved by the boards of directors of each company and the shareholders of Alantos.

    ALS 2-0426 is an orally administered inhibitor of DPP-IV, which in turn inactivates glucagon-like peptide-1 (GLP-1), a mediator of blood glucose levels following meals. Studies suggest that ALS 2-0426 is potent, highly selective, and can be administered once per day. Phase IIa studies were initiated in May in collaboration with Servier, the development and ex-U.S. commercialization partner for the compound.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?